VHCP Management III, LLC bought $1.4M of Oruka Therapeutics (ORKA)
Executed Feb 11 2025, disclosed Feb 27 2025, 16 days later, against a two-business-day limit.
Over the 21 trading sessions from the disclosed entry session (Feb 27 2025), the stock returned +13.9% (delay-adjusted); from the execution session (Feb 11 2025), +6.9%. Derived: entry at the session's open, exit at the close 20 sessions later.
VHCP Management III, LLC (10% owner) filed 2 Form 4 reports as a reporting entity in the past 24 months (2 purchases, 0 sales, 1 filed past the two-business-day deadline), most often in KALV. Across 1 priced purchase filing, the average 21-session return was +6.9% from execution and +13.9% from disclosure (delay-adjusted; derived). The largest single filing was $1.4M of ORKA (122,308 sh across 4 lots, as filed), executed Feb 11 2025.
Healthcare · Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psor…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→